Biomarin Pharmaceutical Stock In The News
| BMRN Stock | USD 69.44 1.16 1.64% |
Our overall analysis of Biomarin Pharmaceutical's news coverage and content from conventional and social sources shows investors' bearish mood towards Biomarin Pharmaceutical. The specific impact of Biomarin Pharmaceutical news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Biomarin Pharmaceutical's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Biomarin Pharmaceutical headlines in addition to utilizing other, more conventional financial analysis modules. Check out Biomarin Pharmaceutical Backtesting and Biomarin Pharmaceutical Hype Analysis. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
Biomarin |
Biomarin Pharmaceutical Today Top News and Investor Outlook
Biomarin Pharmaceutical Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Biomarin and other traded companies coverage with news coverage. We help investors stay connected with Biomarin headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Biomarin Stock performance. Please note that trading solely based on the Biomarin Pharmaceutical hype is not for everyone as timely availability and quick action are needed to avoid losses.
Biomarin Pharmaceutical stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Biomarin earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Biomarin Pharmaceutical that are available to investors today. That information is available publicly through Biomarin media outlets and privately through word of mouth or via Biomarin internal channels. However, regardless of the origin, that massive amount of Biomarin data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Biomarin Pharmaceutical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Biomarin Pharmaceutical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Biomarin Pharmaceutical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Biomarin Pharmaceutical alpha.
Biomarin Largest EPS Surprises
Earnings surprises can significantly impact Biomarin Pharmaceutical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2008-08-05 | 2008-06-30 | 0.03 | 0.04 | 0.01 | 33 | ||
2008-02-26 | 2007-12-31 | 0.04 | 0.03 | -0.01 | 25 | ||
2009-07-30 | 2009-06-30 | -0.01 | 0.01 | 0.02 | 200 | ||
2008-10-28 | 2008-09-30 | 0.03 | 0.01 | -0.02 | 66 | ||
2007-08-07 | 2007-06-30 | -0.06 | -0.04 | 0.02 | 33 | ||
2007-02-20 | 2006-12-31 | -0.13 | -0.11 | 0.02 | 15 |
Biomarin Pharmaceutical Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Biomarin Pharmaceutical Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
13th of March 2025
AMRNs Q4 Earnings Lag Estimates, Stock Down on Ratio Change Plan at zacks.com
11th of March 2025
PTGX Up as JJ-Partnered Drug Meets Goal in Ulcerative Colitis Study at zacks.com
10th of March 2025
EC Approves Bristol Myers Opdivo Plus Yervoy for First-Line HCC at finance.yahoo.com
6th of March 2025
Disposition of 7034 shares by Guyer Charles Greg of Biomarin Pharmaceutical at 71.276 subj... at zacks.com
5th of March 2025
Why BioMarin Pharmaceutical is a Top Value Stock for the Long-Term at finance.yahoo.com
4th of March 2025
Statutory Profit Doesnt Reflect How Good BioMarin Pharmaceuticals Earnings Are at finance.yahoo.com
3rd of March 2025
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug at finance.yahoo.com
28th of February 2025
BMRN or CSLLY Which Is the Better Value Stock Right Now at finance.yahoo.com
27th of February 2025
How Are Institutional Moves Shaping BioMarin Pharmaceutical Inc. s Market Position at kalkinemedia.com
25th of February 2025
BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 ... at finance.yahoo.com
20th of February 2025
BioMarin Pharmaceutical Inc. Q4 2024 Earnings Call Transcript at insidermonkey.com
18th of February 2025
Hemophilia Market Insights Key Trends and Developments Across Different Types of Hemophili... at finance.yahoo.com
Biomarin Pharmaceutical Investors Sentiment
The influence of Biomarin Pharmaceutical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Biomarin. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Biomarin Pharmaceutical's public news can be used to forecast risks associated with an investment in Biomarin. The trend in average sentiment can be used to explain how an investor holding Biomarin can time the market purely based on public headlines and social activities around Biomarin Pharmaceutical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Biomarin Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Biomarin Pharmaceutical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Biomarin Pharmaceutical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Biomarin Pharmaceutical.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Biomarin Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Biomarin Pharmaceutical's short interest history, or implied volatility extrapolated from Biomarin Pharmaceutical options trading.
Check out Biomarin Pharmaceutical Backtesting and Biomarin Pharmaceutical Hype Analysis. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.21 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.